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a b s t r a c t
Deﬁnite evidence has been established such that coronary patients beneﬁt from appropriate
secondary prevention. A series of EUROASPIRE surveys evaluated the level of implementa-
tion of coronary heart disease (CHD) prevention Guidelines. We aimed to evaluate the
changes in adherence to treatment targets during 16 years and to compare the mortality in
Czech patients with manifest CHD.
Four independent descriptive surveys were undertaken in 1995/96, 1999/2000, 2006/07
and 2012/13. Consecutive patients less than 71 years of age suffering for acute coronary
event and/or revascularization procedure were identiﬁed and examined at least 6 months
afterwards.
The study population included 4 series of 331, 410, 421 and 372 patients.
The prescription of basic pharmacotherapy markedly improved, namely use of statins
increased more than 12 times (from 7.3% to 93.3%). Proportion of patients who underwent
revascularization increased from 49% to 95%. Prevalence of hypercholesterolemia and raised
blood pressure signiﬁcantly decreased from 87% to 39% and from 64% to 40%, respectively.
10-years all-cause mortality rates decreased signiﬁcantly between 1995 and 1999 from 28%
to 18%. On the other hand, proportion on smoking did not change signiﬁcantly, while
prevalence of overt diabetes increased more than twice. In conclusion, in spite that the
compliance with the recommendations for secondary prevention markedly improved in
single factors, global achievement of desired target remained rather unsatisfactory, likewise
in other European countries.
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The ultimate goal of treatment of patients with coronary heart
disease (CHD) is to reduce the case fatality, risk of recurrent
cardiovascular event, extend life-time and improve its quality.
Management of patients with manifest coronary heart disease
was deﬁned extensively by the series of Joint European Societies'
Guidelines since 1994 [1–4]. To describe the clinical reality in
secondary prevention of CHD with respect to adherence to these
guidelines, the EUROASPIRE (European Action on Secondary
Prevention by Intervention to Reduce Events) project was
started. The ﬁrst EUROASPIRE I [5] survey was done in 1995–96
in nine European countries, EUROASPIRE II [6] in 1999–2000 in
15 countries, while EUROASPIRE III [7] in 2006–2007 in 22 coun-
tries and EUROASPIRE IV in 2012–2013 in 25 countries; the Czech
centers were involved in all these four surveys.
Since political change in 1989, the Czech Health care system
has markedly improved. The use of modern techniques, before
these political changes rather unavailable, changed dramati-
cally namely in cardiovascular medicine. The accessibility and
general use of all up-to-date pharmacotherapies equalized
with Western Europe, revascularization procedure became
common in nearly all manifest coronary patients. From
epidemiological point-of-view, the life-expectancy increased
by more than 10 years during 90s and the life-style changed
completely. We aimed to establish whether the adherence to
secondary prevention target also improved between 1995 and
2012, and moreover, to analyze the corresponding changes in
mortality outcomes in Czech patients with stable manifest
coronary heart disease.
Methods
Design and study sample
The present study was designed as cross-sectional and
represents a comparison of four independent samples of
patients with stabilized manifest coronary heart disease,
conducted in 1995–96, 1999–2000, 2006–7 and 2012–13 (Czech
samples of EUROASPIRE I, II, III and IV surveys). The sample
selection was in details described elsewhere [5–7]. Brieﬂy,
patients hospitalized for any of following discharge diagnose
and aged less than 71 years at time of this hospitalization were
retrospectively identiﬁed from hospital records: ﬁrst coronary
bypass graft (CABG), ﬁrst percutaneous trans-luminal coro-
nary angioplasty (PTCA) and acute myocardial infarction or
ischemia. Recruitment of patients started with most recent
hospital record and proceeded backwards until the required
sample of 525 subjects in each survey (EUROASPIRE I, II, III and
IV) was achieved (EUROASPIRE III and IV includes moreover a
separate recruitment of patients aged 71–80 years; however
these subjects was excluded from present analysis to prevent
the age discrepancy). All 4 surveys were conducted in two
same centers in Czech Republic: University Hospital in Pilsen
and Cardiologic Centre of Institute of Clinical and Experimen-
tal Medicine in Prague. Both centers represented the universi-
ty-type hospitals with catchment areas of more than 500 000
inhabitants, offering all types of cardiologic care (acutemanagement of myocardial infarctions, interventional cardi-
ology, cardio-surgery, etc.)
Procedures
The standard protocol of EUROASPIRE (EA) survey was followed,
as described elsewhere [5–7]. Brieﬂy, patients were interviewed
at least 6 moths after their index event (acute coronary
syndrome or ﬁrst elective revascularization). Information on
personal and demographic characteristics, personal and family
history of coronary heart disease, life-style and pharmacother-
apy were obtained. The following standardized examinations
were performed: Height and weight were measured in light
indoor clothes without shoes using SECA 707 (EA I and II) and
SECA 701 (EA III and IV) scales and measuring stick. The scales
were calibrated at the start of each survey. Waist circumference
was measured using tape measure. Blood pressure (BP) was
measured twice in the sitting position on the right arm using
automated sphygmomanometers (Takeda UA731 in EA I,
Omron 711 in EA II, Omron M5-I in EA III and Omron M6 in
EA IV). A series of comparisons of these different devices was
done, always using 100 randomly ordered measurements and
the relevant blood pressures were systematically adjusted for
observed measurement bias (which was in fact not greater than
0.95/+2.64 mmHg). Breath carbon monoxide was measured by
Smokerlyser device (Bedfont Scientiﬁc, UK). Venous blood
samples were drawn after at least 12 h of overnight fast. The
laboratory examinations included estimation of total (TCHOL)
and HDL cholesterol (HDL), triglycerides (TG) and glucose (GLU),
and were performed at the central study laboratories of
respective EUROASPIRE survey. Again, laboratory methods
were described elsewhere [5–7] and comparability of laboratory
parameters of both surveys was validated using repeated
analyses of long-term stored frozen samples. LDL cholesterol
was calculated by Friedewald equation, i.e. LDL = TCHOL 
HDL  (TG/2.22).
Data management
Vital status of patients was registered up to May 31, 2012 using
National mortality registry of Czech Department of Medical
Information and Statistics of Ministry of Health in Prague in EA
I–III subjects. Death certiﬁcates were used to specify the cause
of death.
Statistical analysis was done using software STATISTICA 8.
Continuous risk factors were categorized using target values of
1st, 2nd, 3rd and 4th Joint European guidelines [1–4] (for
deﬁnitions and statistical methods see table footnotes and
other speciﬁc parts of results section). All data were stored
under the provisions of the Czech data protection act. The whole
study was carried under Good Clinical Practice regulations; the
study protocol was approved by local Ethical Committee and all
study participants signed the Informed consent form.
Results
A total of 525 medical records were reviewed in the course of
each of four surveys, while 331, 410, 421 and 372 interviewed
patients were analyzed in the present paper; giving overall
Table 1 – Cross-sectional characteristics and risk profile among Czech patients with manifest coronary heart disease in
EUROASPIRE I, II, III and IV surveys younger than 71 years at time of coronary event of procedure [mean (SD)].
Pooled
data
Pooled
data EA I–III
EA I
[1995–96]
EA II
[1999–2000]
EA III
[2006–07]
EA IV
[2012–13]
p for trend
[EA I–IV]
n 1534 1162 331 410 421 372
Age 60.3 (7.8) 59.6 (7.79) 59.0 (8.5) 59.2 (7.8) 60.3 (7.0) 62.3 (7.4) <0.0001
Gender [% of males] 77.4 75.5 70.7 73.4 81.1 83.3 <0.0001
Time to interviewb [years] 1.44 (0.58) 1.50 (0.55) 1.57 (0.53) 1.76 (0.54) 1.16 (0.41) 1.28 <0.0001
Any coronary revascul. 75.5 74.3 48.8 72.7 95.7 95.4 <0.0001
Current smoking [%] 22.3 22.4 24.6 19.8 22.7 21.8 0.39a
Body mass index [kg/m2] 29.3 (4.5) 29.3 (4.55) 28.6 (4.2) 29.5 (4.6) 29.3 (4.5) 29.5 (4.3) <0.0009a
Waist circumference [cm] 101.2 (11.9) 100.0 (11.8) 98.0 (11.7) 99.3 (11.2) 102.1 (11.1) 104.8 (11.6) <0.0001a
Systolic BP [mmHg] 140.0 (20.4) 141.5 (20.9) 144.1 (22.2) 136.5 (20.2) 145.0 (20.0) 135.5 (17.9) <0.0001a
Diastolic BP [mmHg] 83.9 (11.3) 84.4 (11.5) 87.5 (11.4) 80.7 (10.5) 85.5 (11.8) 82.3 (10.4) <0.0007a
Total cholesterol [mmol/L] 5.01 (1.28) 5.23 (1.29) 5.41 (0.91) 5.70 (1.24) 4.62 (1.33) 4.36 (1.01) <0.0001a
HDL cholesterol [mmol/L] 1.20 (0.33) 1.23 (0.34) 1.20 (0.33) 1.24 (0.40) 1.23 (0.30) 1.14 (0.25) 0.09*
LDL cholesterol [mmo/L] 2.98 (1.09) 3.18 (1.08) 3.40 (0.82) 3.68 (1.09) 2.55 (0.91) 2.37 (0.80) <0.0001a
Triglycerides [mmol/L] 1.88 (1.49) 1.89 (1.57) 1.97 (1.25) 1.72 (0.93) 1.93 (2.14) 1.89 (1.14) 0.21a
Fasting glucose [mmol/L] 6.97 (2.41) 6.97 (2.50) 6.53 (2.46) 6.90 (2.33) 7.31 (2.50) 6.68 (2.09) <0.02a
BP, blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
a p-Value adjusted for age and gender.
b An interval between qualifying coronary event or procedure and study interview.
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ly. Table 1 presents demographic and clinical characteristics of
responders among four surveys separately, the pooled data of
all four and of EA I–III only (for the purpose of mortality
analysis). Subjects of EA III and IV were very slightly, but
already signiﬁcantly older and the sample consisted of more
males, than previous surveys (therefore all statistical compar-
isons were systematically adjusted for age and gender).
Smoking prevalence did not change over time, while body
mass index (BMI) and waist circumference showed the
increasing trends. Comparing EA I and EA IV, both, systolic
(SBP) and diastolic blood pressure (DBP) decreased signiﬁcantly
by about 9/5 mmHg in average. Mean total and LDL cholesterol
concentrations decreased signiﬁcantly over time, while HDL
and TG remained virtually unchanged. A signiﬁcant increase
was found in fasting glycaemia between EA I and III, than
decrease slightly again. Proportion of coronary revasculariza-
tion procedures (either PTCA or CABG, in the course of index
event or between index event and interview) also consistently
increased from EA I to IV about twice up to 95% of patients.
Risk factors categorized with respect to 1st, 2nd, 3rd and 4th
Joint European Guidelines targets are given in Table 2 and non-
adherence (i.e. % of patients exceeding the target value) to
currently applicable value (i.e. target at time of interview with
respect to currently effective Guidelines) are highlighted in
bolt. As can be expected, namely prevalence of hypercholes-
terolemia (by several deﬁnitions) and raised blood pressure
signiﬁcantly dropped between EA I and IV. In contrast, obesity,
waist circumference and namely proportion of all categories of
impaired glucose metabolism increased signiﬁcantly. General
trends in adherence to target value, truly effective at time of
interview are summarized in Fig. 1.
Basic pharmacotherapy in secondary prevention used is
also given in Table 2. The prescription rate increased
signiﬁcantly in all selected categories, the highest increase
was found in statins (more than 12 times).Mortality was estimated in 1162 participants of EA I–III
surveys. In pooled data of these surveys, 301 patients died until
May 31, 2012 during median (interquartile range) of follow-up
was 9.23 (5.60–12.59) years. Of them, 186 died from cardiovas-
cular cause and 75 from malignancy (using ICD-10 codes of
primary cause of death from death certiﬁcates)
Time-standardized all-cause and speciﬁc mortality rates
are given in Table 3. No signiﬁcant differences between three
EA surveys were found in 5-year all-cause and cardiovascular
mortality, in spite that a non-signiﬁcant decreasing trend
between EA I and II can be observed. The 10-year all-cause
mortality showed a substantial decrease between EA I and II,
however accountable more to decrease in mortality from
malignancies that to cardiovascular cause of deaths.
Discussion
Our study consisted of 4 independent samples of patients with
manifest coronary heart disease, i.e. of those who experienced
acute coronary syndrome or coronary revascularization
procedure. The primary aim was to validate the changes in
cardiologic care in chronic coronary patient over more than 16
years in Czech Republic. Generally, the study brought the mix
of favorable and less favorable facts. A large increase in
prescription of all drug-classes beneﬁcial in secondary
prevention of CHD should be considered as highly favorable.
Namely the prescription of statins rose dramatically more
than 12 times and also prescription-rate of all other basic drug-
classes for secondary prevention of CHD (e.g. aspirin,
betablockers and ACEIs or ARBs) was in 2012 80–95% and
probably reached the yield of achievability (with respect to
eventual contraindications and compliance of patients). The
‘‘dark side’’ of pharmacotherapy in secondary prevention is
un-appropriate dosing, leading to inadequate proportion of
patients reaching the target values and in some cases use of
Table 2 – Non-adherence to target values of 1st, 2nd, 3rd and 4th Joint Guidelines [1–4] for cardiovascular prevention and
treatment used in Czech EUROASPIRE I, II, III and IV surveys [%].
EA I EA II EA III EA IV p for trend
Overweight
BMI  25 kg/m2 82.3 87.4 85.2 86.6 0.43
BMI  30 kg/m2 32.9 40.2 38.4 43.8 <0.002
BMI  40 kg/m2 1.5 2.2 3.7 2.2 0.06
Increased waist circumference
Action zone 1 (94–101c/80–87d cm) 27.8 26.8 27.6 21.0 <0.03
Action zone 2 (102c/88d cm) 50.8 52.5 56.7 68.3 <0.0001
Raised blood pressure
SBP  140 and/or DBP  90 mmHg 63.7 43.6 60.1 39.5 <0.0001
SBP  140 and/or DBP  90 or SBP  130 and/or
DBP  80 in diabeticsa
69.2 49.5 70.6 55.4 <0.0001
SBP  130 and/or DBP  80 83.8 73.4 83.5 74.5 <0.0001
SBP  180 and/or DBP  110 mmHg 18.4 6.7 11.9 5.1 <0.0001
Hypercholesterolemia
TCHOL  4.5 mmol/L 85.2 86.6 47.9 40.1 <0.0001
TCHOL  5 mmol/L 66.0 72.9 27.9 22.5 <0.0001
LDL  2 mmol/L 95.9 95.4 74.2 64.0 <0.0001
LDL  2.5 mmol/L 87.3 88.5 48.1 38.6 <0.0001
LDL  3 mmol/L 67.2 75.9 25.4 17.6 <0.0001
Low HDL cholesterol
HDL < 1cor 1.2d mmol/L 35.7 29.4 32.6 35.1 0.65
HDL < 1 mmol/L 30.2 24.7 27.1 30.1 0.91
HDL < 1cor 1.1d mmol/L 32.3 27.2 27.9 32.9 0.46
Hypertriglyceridemia
TG  1.7 mmol/L 49.8 38.8 45.2 44.2 0.80
TG  2.0 mmol/L 36.1 29.4 29.5 30.4 0.43
TG  2.3 mmol/L 27.5 20.1 23.6 22.8 0.77
Impaired glucose metabolism
Glucose  6.1 mmol/L 41.6 56.3 72.4 59.9 <0.0001
Glucose  7 mmol/L 20.2 23.8 36.2 37.9 <0.0001
Overt diabetesa 23.4 25.1 45.7 47.7 <0.0001
Impaired fasting glucoseb 19.7 31.5 30.7 16.5 <0.0001
Reported treatment
Aspirin [%] 80.7 87.2 88.4 90.6 <0.0002
Aspirin or anticoagulants [%] 87.9 87.5 93.1 94.6 <0.0001
Any antihypertensives [%] 79.9 90.2 94.5 98.4 <0.0001
Betablockers [%] 56.7 74.0 88.1 86.8 <0.0001
ACEIs or ARBs [%] 23.8 46.9 73.9 80.6 <0.0001
Any lipid-lowering drugs [%] 28.0 56.8 88.5 94.1 <0.0001
Statins [%] 7.3 38.6 83.1 93.3 <0.0001
Antidiabetics [%] 9.8 12.3 18.5 29.6 <0.0001
BMI, body mass index; SBP, systolic blood pressure; DBP, systolic blood pressure; TCHOL, total cholesterol; ACEIs, angiotensin converting
enzyme inhibitors; ARBs, angiotensin receptor blockers.
p-Value adjusted for age and gender, target value of lipids and glucose at time of interview with respect to currently effective Guidelines) are
highlighted in bolt.
a Fasting glucose  7 mmol/L or treatment with antidiabetics.
b Fasting glucose 6.1–6.9 mmol/L but no treatment with antidiabetics.
c Males
d Females.
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about 15% increase in prescription of antihypertensives, the
blood pressure control did not change practically when
comparing EA I and EA III (and improved not-until the last
period 2006–12).
Very exciting trend was observed in revascularization
procedures. More than 95% of patients in EA III and IV
underwent either PTCA or CABG and absolute majority (more
than 90%) of acute myocardial infarction patients underwent
PTCA in acute phase. On the other hand, unused full potential
of secondary prevention may result into less individual beneﬁtof sophisticated approach in acute phase, than can be
expected.
Management of dyslipidemia also improved substantially
across the four surveys, and this is attributable mainly to wide
use of statins. The target LDL concentration is now being
achieved by more than three-ﬁfth of all patients. On the other
hand, recent 5th Joint European Guidelines [8] lowered the
target to LDL < 1.8 mmol/L. This new target is based on very
convincing evidence [9] and will be even greater challenge for
clinical practice. Currently, only about 23% of patients reach
this new target LDL < 1.8 mmol/L in our series. To get this new
Fig. 1 – Trends in adherence to risk factor targets with respect to values truly effective at time of interview (as defined by 1st,
2nd, 3rd and 4th Guidelines [1–4]). The definitions used are in EA I, EA II, EA III and EA IV as follows: obesity BMI I 30 kg/m2;
uncontrolled blood pressure I BP140/90, 140/90, 140/90 or 130/80 in diabetic patients and 130/80 mmHg, respectively; raised
total/LDL cholesterol TCHOL I 5, LDL I 3, LDL I 2.5 and LDL I 2.5 mmol/L, respectively; low HDL cholesterol HDL <1 in males
or HDL <1.1, 1, 1.2 and 1.2 mmol/L, respectively in females; hypertriglyceridemia TG I 2.3, 2, 1.7 and 1.7, respectively;
inadequate glucose levels fasting glyceamia I 7, 6.1, 6.1 and 6.1, respectively.
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of statins will be substantial. The dosage habit in lipid-
lowering drugs in EA III survey was analyzed in our previous
paper [10]. Only less than 5% of patients were treated with
doses of statin equivalent to 80 mg simvastatin and vice versa,
about 38% with only substandard dose (equivalent of 20 mg of
simvastatin), despite that 43% of these patients did not reach
the current LDL target 2.5 mmol/L yet. In the last years dosage
habit in secondary prevention probably improved, EA IV data
showed that about 56% of patients are now treated withTable 3 – All-cause and specific mortalities among responders
EA I [1995–96] EA II [199
All-cause mortality
1 year 1.7 2.2
2 years 5.3 3.7
5 years 12.2 8.1
10 years 27.7 17.9
Cardiovascular diseases
1 year 1.7 1.5
2 years 2.3 2.7
5 years 5.3 5.4
10 years 14.9 11.3
Malignancies
5 years 4.6 2.0
10 years 7.9 3.4
p-Value adjusted for age and gender.equivalent of 80 mg of simvastatin. However, only 1.8% are
treated by maximal available dose of statin (i.e. 80 mg of
atorvastatin or 40 mg of rosuvastatin). The question remained
about new lipid-lowering classes suitable for combination
treatment. Ezetimibe showed a fair lipid-lowering potential in
combination with statin, but we are still lacking the evidence
of its mortality beneﬁt (and these data will be available not
sooner than in next year). Very promising is this context
is another new class of LDL-lowering drugs, i.e. PCSK-9
(proprotein-convertase subtilysin/kexin 9) inhibitors, but of EUROASPIRE I, II and III surveys [%].
9–2000] EA III [2006–07] p
 1.7 0.58
 2.6 0.052
 9.5 0.47
 – <0.002
 1.0 0.14
 1.4 0.38
 5.5 0.42
 – 0.14
 3.6 0.27
 – <0.009
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than in 2016/17. Thus, underuse of high-dose statin treatment
represents probably the most important unused potential
to improve the secondary prevention in current clinical
practice.
An alarming trend was found in diabetes. The prevalence of
type 2 diabetes among CHD patients increased between 1995
and 2012 by more than twice, and moreover further ca. 17% of
patients showed impaired fasting glucose (as pre-diabetic
status). The problem of impaired glucose metabolism and
related ﬁelds are more in detail analyzed and discussed by
another paper (in this issue of Cor et Vasa).
Smoking prevalence did not change over time and
remains on about 20% of patients. None of the smokers
get a supportive treatment for quitting smoking (such as
bupropion or varenicline), and the absolute majority of ex-
smokers quit the smoking spontaneously at the time of its
myocardial infarction or revascularization. In conclusion,
the overall approach to this problem is in clinical practice
obviously ‘‘nihilistic’’, and unfortunately, we did not see any
trend to improvement. Rather negative role plays in these
context a very benevolent anti-smoking legislation in Czech
Republic.
Being part of EUROASPIRE project from the beginning we
are able to consider, how the situation in secondary prevention
practice in Czech Republic differs from those in developed
Western European countries [11,12]. Generally, trends in
particular risk factors in Czech Republic in fact copy those
in Western European countries. In several factors such as
control of hypertension or dyslipidemia and prevalence of
smoking we are very close to average rates (or slightly better).
The prescription rates of lipid-lowering medication and
ACEi/ARB' are very fair, while unfavorable trends showed
diabetes and obesity (in spite that diabetes increased in all
European countries involved in EA studies).
The second part of the present study was the mortality
analysis. Over time, we observe a decreasing trend in total
mortality, in spite that statistical signiﬁcance reached only
difference in 10-year mortality between 1995 and 2000 surveys.
It is questionable, whether this mortality decrease can be
attributed to better treatment in acute phase and/or in
secondary prevention, because the differences in cardiovas-
cular mortality did not reach statistical signiﬁcance (and
paradoxically, statistically signiﬁcant was the decrease in
malignancies). We are not able to review the individual cause
of death because of lacking case documentation (several
subjects died at home) and therefore we depend on reliability
of declared primary cause of death. On the other hand,
mortality in chronic CHD patients seems to be fairly low in our
country and in fact very close to general population mortality
rates.
Our study has several limitations. The patients were
identiﬁed from selected geographical area around specialized
cardiologic centers and thus are not a representative sample of
all patients with CHD in the Czech Republic. Therefore, the
reality of preventive cardiology practice might be even worse.
The limitation of mortality analysis is that we included
relatively stable patient, i.e. those who survived at least 6
months (1.42 years in median) after the coronary event or
revascularization and showed perhaps lower mortality-risk ascan be expected (i.e. the seriously ill patients died before the
interview). Furthermore, no information is available on
recurrent non-fatal vascular events.
The certain problem for interpretation is that target value
deﬁnitions of several risk factors substantially changed over
time (from 1st to 4th Joint European Guidelines). To evaluate
the global change in secondary prevention practice (i.e.
adherence to target values), we must compare differently
deﬁned variables. Namely, blood pressure target changed from
140/90 in 1st and 2nd Task Force Guidelines to 140/90 or 130/80
in diabetic patients in 3rd and ﬁnally to 130/80 in all patients in
secondary prevention (while returned back to 140/90 in the 5th
Task Force Guidelines) [1–4,8]. Even more changes occurred in
cholesterol targets. The ﬁrst guidelines used generally total
cholesterol as target parameter of treatment, while later
Guidelines used already LDL values as targets (LDL < 3 in the
2nd, LDL < 2.5 in 3rd/4th Guidelines and even <1.8 in the
newest ones). Therefore, we depict all existing target values in
Table 2, and Fig. 1 summarized adherences to target values,
truly effective at time of interview. Another problem is that EA
IV trial was realized few months after 5th Joint Guidelines [8]
was already published. We supposed that this newest
guidelines was at time of interview only very poorly
implemented into clinical practice and therefore we used
4th Guidelines target values to categorize the risk proﬁle of EA
IV subjects.
Overt diabetes was in our analysis deﬁned as fasting
glucose 7 mmol/L and/or treatment with antidiabetics. This
deﬁnition probably slightly underestimates the reality, be-
cause we omit those patients with manifest diabetes who
underwent the compensation using only non-pharmacologic
approach. Moreover some patients might exhibit fasting
glucose <7, but after glucose load will be categorized as
diabetic (the oral glucose tolerance test was realized only in EA
IV trial and these data are not used in the present analysis). It is
supposable that majority of these subjects ‘‘falled’’ onto
category of impaired fasting glucose.
In conclusion, clinical practice in secondary prevention
between 1995 and 2012 substantially improved in terms of
routine prescription of basic pharmacotherapy (namely
statins) and moreover in proportion of revascularization
procedures. On the other hand, the therapeutic control to
recommended targets remains far from being optimal. Long-
term cardiovascular mortality is rather low, but we cannot
conﬁrm a further signiﬁcant decrease.
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